Guanfacine to Improve Substance Use Outcomes in Women
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 100
Summary
- Conditions
- Substance Use Disorders
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: randomized double blindMasking: Double (Participant, Care Provider)Masking Description: double blindPrimary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Only males
Description
This study proposes to extend previous Phase I experimental work to address the following specific aims: (1) assess GUA's target engagement of drug craving and cognitive flexibility in a laboratory challenge session and in a 10-week outpatient clinical study, (2) demonstrate target validation by sho...
This study proposes to extend previous Phase I experimental work to address the following specific aims: (1) assess GUA's target engagement of drug craving and cognitive flexibility in a laboratory challenge session and in a 10-week outpatient clinical study, (2) demonstrate target validation by showing that reduced drug craving and improved cognitive flexibility will predict lower drug use outcomes during the 10-week clinical trial in SUD women, and finally, (3) evaluate data replication and scalability of GUA target effects across two clinical sites (Yale and SUNY-Stony Brook).
Tracking Information
- NCT #
- NCT03980184
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Investigators
- Principal Investigator: Rajita Sinha, PhD Yale University
Get Well Soon